Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer

KCSN are formal consultants to NICE and part of the process that appraises all new kidney cancer drugs. We are delighted to tell you that, as from today, kidney cancer patients can get NHS funding via the Cancer Drugs Fund for avelumab in combination with axitinib as a first-line treatment for patients with untreated advanced […]

read more

Proposed changes to NICE appraisal process to enable faster access to cost-effective treatments

The National Institute for Health and Care Excellence (NICE) and NHS England are proposing changes to the process for evaluating and funding drugs and other health technologies, and have launched a joint 12-week consultation, ‘Proposals for changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE’s technology appraisal and highly […]

read more
Showing all 2 results
  TOP